

Biomarkers Workshop

- Don Goff and Steven Potkin presented the summary of survey results of 129 ISCTM members regarding use of Biomarkers in Schizophrenia.
- Discussion of issues with biomarkers development and evaluation
- Discussion points: Realization that biomarkers are rarely compared in same study making comparative evaluation difficult
- Next steps: need for a prospective study with a design includes simultaneous measurement of a variety blood measure, genomic including DNA methylation, cognitive , EEG and brain imaging
 - Goal: determine relevance of various biomarkers to stage and severity of illness, course of illness; relationship between biomarkers; and samples sizes needed for change in biomarkers should they be used as enrichment or outcome for clinical trials; diagnoses to be included; comparison of most studied and best biomarkers
 - Biomarkers characteristics: variability, state v trait; reproducibility; ease of use
- Use ADNI as model for designing a Schizophrenia ADNI:
 - Prospective follow-up , shared data, joint responsibility; variety of expertise needed
 - Partnership of Industry, academia, and NIH was essential